Proteasome inhibitors as therapeutic agents

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 1, 2003, Pages 45-57

  Adams, Julia ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Apoptosis; Cancer; Peptide boronate; Proteasome inhibitor

Indexed keywords

AMYLOID BETA PROTEIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORONIC ACID DERIVATIVE; BORTEZOMIB; CALPASTATIN; CEP 1612; CHYMOTRYPSIN; CISPLATIN; CYSTEINE PROTEINASE; EPIGALLOCATECHIN GALLATE; EPONEMYCIN; EPOXOMICIN; GEMCITABINE; GLIOTOXIN; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; LACTONE DERIVATIVE; MG 262; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P53; TMC 95; TRANSCRIPTION FACTOR; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YU 101;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE; CELL DIVISION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG DISTRIBUTION; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; INFLAMMATION; METABOLIC DISORDER; NONHUMAN; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW;

EID: 0037234688     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.1.45     Document Type: Review

References (124)

1. CLURMAN BE, SHEAFF RJ, THRESS K, GROUDINE M, ROBERTS JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by CDK2 binding and cyclin phosphorylation. Genes Dev. (1996) 10(16):1979-1990.
2. BOUNPHENG MA, DIMAS JJ, DODDS SG, CHRISTY BA. Degradation of Id proteins by the ubiquitin-proteasome pathway. FASEB J. (1999) 13(15):2257-2264.
3. DESAI SD, LIU LF, VAZQUEZ-ABAD D, D'ARPA P: Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumour drug camptothecin. J. Biol. Chem. (1997) 272(39):24159-24164.
4. MAKI CG, HUIBREGTSE JM, HOWLEY PM: In vivo ubiquitylation and proteasome-mediated degradation of p53(1). Cancer Res. (1996) 56:(11):2649-2654.
5. LI B, DOU QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumour survival and progression. Proc. Natl. Acad. Sci. USA (2000) 97(8):3850-3855.
6. KUMATORI A, TANAKA K, INAMURA N et al.: Abnormally high expression of proteasomes in human leukemic cells. Proc. Natl. Acad. Sci. USA (1990) 87:(18):7071-7075.
7. LAVABRE-BERTRAND T, HENRY L, CARILLO S et al.: Plasma proteasome level is a potential marker in patients with solid tumours and hemopoietic malignancies. Cancer (2001) 92(10):2493-2500.
8. OWA T, YOSHINO, H, YOSHIMATSU K, NAGASU T: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr. Med. Chem. (2001) 8(12):1487-1503.
9. TEICHER BA, ARA G, HERBST R, PALOMBELLA VJ, ADAMS J: The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. (1999) 5(9):2638-2645.
10. ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumour agents. Cancer Res. (1999) 59(11):2615-2622.
11. BOLD RJ, VIRUDACHALAM S, MCCONKEY DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J. Surg. Res. (2001) 100(1):11-17.
12. BERENSON JR, MA HM, VESCIO R: The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin. Oncol. (2001) 28(6):626-633.
13. CUSACK JC Jr, LIU R, HOUSTON M et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. (2001) 61(9):3535-3540.
14. RUSSO SM, TEPPER JE, BALDWIN AS et al.: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50(1):183-193.
15. PERVAN M, PAJONK F, SUN JR, WITHERS HR, MCBRIDE WH: Molecular pathways that modify tumour radiation response. Am. J. Clin. Oncol. (2001) 24(5):481-485.
16. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: Phase II study of the proteasome inhibitor PS-341 in multiple myeloma patients (pts) with relapsed/refractory disease: results from cohort 1 analysis. 38th Annual Meeting of the American Society of Clinical Oncology Orlando, FL (May 17-24, 2002). Proceedings of the American Society of Clinical Oncology (2002) 21:11a.
17. HERSHKO A, CIECHANOVER A: The ubiquitin system. Annu. Rev. Biochem. (1998) 67:425-479.
18. ROTH AF, DAVIS NG: Ubiquitylation of the PEST-like endocytosis signal of the yeast α-factor receptor. J. Biol. Chem. (2000) 275(11):8143-8153.
19. MARCHAL C, HAGUENAUER-TSAPIS R, URBAN-GRIMAL D: A PEST-like sequence mediates phosphorylation and efficient ubiquitylation of yeast uracil permease. Mol. Cell Biol. (1998) 18(1):314-321.
20. CONAWAY RC, BROWER CS, CONAWAY JW: Emerging roles of ubiquitin in transcription regulation. Science (2002) 296(5571):1254-1258.
21. EYTAN E, GANOTH D, ARMON T, HERSHKO A: ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc. Natl. Acad. Sci. USA (1989) 86(20):7751-7755.
22. BRANNIGAN JA, DODSON G, DUGGLEBY HJ et al.: A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature (1995) 378(6555):416-419.
23. ROHRWILD M, COUX O, HUANG HC et al.: HslV-HslU: A novel ATP-dependent protease complex in Escherichia coli related to the eukaryotic proteasome. Proc. Natl. Acad. Sci. USA (1996) 93(12):5808-5813.
24. LUPAS A, KOSTER AJ, BAUMEISTER W: Structural features of 26S and 20S proteasomes. Enzyme Protein (1993) 47(4-6): 252-273.
25. TOKUNAGA F, GOTO T, KOIDE T et al.: ATP- and antizyme-dependent endoproteolysis of ornithine decarboxylase to oligopeptides by the 26 S proteasome. J. Biol. Chem. (1994) 269(26):17382-17385.
26. KISSELEV AF, GOLDBERG AL: Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. (2001) 8(8):739-758.
27. WILKINSON KD: Ubiquitylation and deubiquitylation: targeting of proteins for degradation by the proteasome. Semin. Cell Dev. Biol. (2000) 11(3):141-148.
28. LARSEN CN, PRICE JS, WILKINSON KD: Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry (1996) 35(21):6735-6744.
29. YANG Y, FANG S, JENSEN JP, WEISSMAN AM, ASHWELL JD: Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science (2000) 288:874-877.
30. CHADEBECH P, BRICHESE L, BALDIN V, VIDAL S, VALETTE A: Phosphorylation and proteasome-dependent degradation of Bcl-2 in mitotic-arrested cells after microtubule damage. Biochem. Biophys. Res. Commun. (1999) 262:823-827.
31. ZHAO J, TENEV T, MARTINS LM, DOWNWARD J, LEMOINE NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell. Sci. (2000) 113:4363-4371.
32. TATEBE H, YANAGIDA M: Cut8, essential for anaphase, controls localization of 26S proteasome, facilitating destruction of cyclin and Cut2. Curr. Biol. (2000) 10:1329-1338.
33. PAGANO M, TAM SW, THEODORAS AM et al.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 269:682-685.
34. CAYROL C, DUCOMMUN B: Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene (1998) 17:2437-2444.
35. NAWAZ Z, LONARD DM, DENNIS AP, SMITH CL, O'MALLEY BW: Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. USA (1999) 96:1858-1862.
36. SEGNITZ B, GEHRING U: The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. (1997) 272:18694-18701.
37. MASUYAMA H, MACDONALD PN: Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR. J. Cell. Biochem. (1998) 71:429-440.
38. SALVAT C, JARIEL-ENCONTRE I, ACQUAVIVA C, OMURA S, PIECHACZYK M: Differential directing of c-Fos and c-Jun proteins to the proteasome in serum-stimulated mouse embryo fibroblasts. Oncogene (1998) 17:327-337.
39. NESBIT CE, TERSAK JM, PROCHOWNIK EV: MYC oncogenes and human neoplastic disease. Oncogene (1999) 18:3004-3016.
40. PALOMBELLA VJ, RANDO OJ, GOLDBERG AL, MANIATIS T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell (1994) 78:773-785.
41. BOYER SN, WAZER DE, BAND V: E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. (1996) 56:4620-4624.
42. ADAMS J, BEHNKE M, CHEN S et al.: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med Chem. Lett. (1998) 8(4):333-338.
43. LEE DH, GOLDBERG AL: Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J. Biol. Chem. (1996) 271(44):27280-27284.
44. SHAH SA, POTTER MW, CALLERY MP: Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surg. Oncol. (2001) 10:(1-2):43-52.
45. DICK LR, CRUIKSHANK AA, GRENIER L et al.: Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clastolactacystin beta-lactone. J. Biol. Chem. (1996) 271(13):7273-7276.
46. FENTEANY G, STANDAERT RF, LANE WS et al.: Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science (1995) 268(5211):726-731.
47. KOZLOWSKI , STOKLOSA T, OMURA S et al.: Lactacystin inhibits cathepsin A activity in melanoma cell lines. Tumour Biol. (2001) 22(4):211-215.
48. ELLIOTT PJ, PIEN CS, MCCORMACK TA, CHAPMAN ID, ADAMS J: Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin. Immunol. (1999) 104(2 Pt 1):294-300.
49. CAMPBELL B, ADAMS J, SHIN YK, LEFER AM: Cardioprotective effects of a novel proteasome inhibitor following ischaemia and reperfusion in the isolated perfused rat heart. J. Mol. Cell Cardiol, (1999) 31(2):467-476.
50. MENG L, MOHAN R, KWOK BH et al.: Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. Proc. Natl. Acad. Sci. USA (1999) 96:(18)10403-10408.
51. MENG L, KWOK BH, SIN N, CREWS CM: Eponemycin exerts its antitumour effect through the inhibition of proteasome function. Cancer Res. (1999) 59(12):2798-2801.
52. MYUNG J, KIM KB, CREWS CM: The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. (2001) 21(4):245-273.
53. KOHNO J, KOGUCHI Y, NISHIO M et al.: Structures of TMC-95A-D: novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J. Org. Chem. (2000) 65(4):990-995.
54. ELOFSSON M, SPLITTGERBER U, MYUNG J, MOHAN R, CREWS CM: Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem. Biol. (1999) 6(11):811-822.
55. NAM S, SMITH DM, DOU QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J. Biol. Chem. (2001) 276(16):13322-13330.
56. PAHL HL, KRAUSS B, SCHULZE-OSTHOFF K et al.: The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-kappaB. J. Exp. Med. (1996) 183(4):1829-1840.
57. ORLOWSKI RZ, ESWARA JR, LAFOND-WALKER A et al.: Tumour growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res. (1998) 58(19):4342-4348.
58. MASDEHORS P, MERLE-BERAL H, MAGDELENAT H, DELIC J: Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk. Lymphoma (2000) 38(5-6):499-504.
59. DELIC J, MASDEHORS P, OMURA S et al.: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo-and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis. Br. J. Cancer (1998) 77(7):1103-1107.
60. MASDEHORS P, MERLE-BERAL H, MALOUM K et al.: Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood (2000) 96(1):269-274.
61. MITSIADES CS, TREON SP, MITSIADES N et al.: TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood (2001) 98(3):795-804.
62. HIDESHIMA T, RICHARDSON P, CHAUHAN D et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61(7):3071-3076.
63. DREXLER HC: Activation of the cell death programme by inhibition of proteasome function. Proc. Natl. Acad. Sci. USA (1997) 94(3):855-860.
64. DREXLER HC, RISAU W, KONERDING MA: Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. (2000) 14(1):65-77.
65. SIU WY, AROOZ T, POON RY: Differential responses of proliferating versus quiescent cells to adriamycin. Exp. Cell Res. (1999) 250(1):131-141.
66. FRANKEL A, MAN S, ELLIOTT P, ADAMS J, KERBEL RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin. Cancer Res. (2000) 6(9):3719-3728.
67. SOLIGO D, SERVIDA F, DELIA D et al.: The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br. J. Haematol. (2001) 113(1):126-135.
68. OYAIZU H, ADACHI Y, OKUMURA T et al.: Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in human lung adenocarcinoma cell line. Oncol. Rep. (2001) 8(4):825-829.
69. KURLAND JF, MEYN RE: Protease inhibitors restore radiation-induced apoptosis to Bcl-2- expressing lymphoma cells. Int. J. Cancer (2001) 96(6):327-333.
70. MA MH, PARKER KM, MANYAK S et al.: Proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma cells to chemotherapeutic agents and overcomes chemoresistance through inhibition of the NF-κB pathway. 43rd Annual Meeting of the American Society of Hematology Orlando, FL (Dec 7-11, 2001). Blood (2001) 98(11): 437a.
71. FEINMAN R, ARIS VM, VERGANO S et al.: Transcriptional gene expression profiles in drug-sensitive and Bcl-2-resistant myeloma cells in response to dexamethasone, arsenic trioxide and PS-341. 43rd Annual Meeting of the American Society of Hematology Orlando, FL (December 7-11, 2001). Blood (2001) 98(11): 368a.
72. AN B, GOLDFARB RH, SIMAN R, DOU QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed but not normal, human fibroblasts. Cell Death Differ. (1998) 5(12):1062-1075.
73. MARSHANSKY V, WANG X, BERTRAND R et al.: Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J. Immunol. (2001) 166(5):3130-3142.
74. DIETRICH C, BARTSCH T, SCHANZ F, OESCH F, WIESER RJ: p53 dependent cell cycle arrest induced by N- acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc. Natl. Acad. Sci. USA (1996) 93(20):10815-10819.
75. MACLAREN AP, CHAPMAN RS, WYLLIE AH, WATSON CJ: p53 dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death. Differ. (2001) 8(3):210-218.
76. FAN XM, WONG BC, WANG WP et al.: Inhibition of proteasome function induced apoptosis in gastric cancer. Int. J. Cancer (2001) 93:(4):481-488.
77. SHAH SA, POTTER MW, MCDADE TP et al.: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. (2001) 82(1):110-122.
78. CHEN C, EDELSTEIN LC, GELINAS C: The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol. Cell Biol. (2000) 20(8):2687-2695.
79. WANG CY, MAYO MW, KORNELUK RG, GOEDDEL DV, BALDWIN AS Jr: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c- IAP1 and c- IAP2 to suppress caspase-8 activation. Science (1998) 281:(5383):1680-1683.
80. BANCROFT CC, CHEN Z, DONG G et al.: Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK- NF-κB signal pathways. Clin Cancer Res. (2001) 7:(2):435-442.
81. CHAUHAN D, UCHIYAMA H, AKBARALI Y et al.: Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood (1996) 87(3):1104-1112.
82. MORI M, TERUI Y, TANAKA M et al.: Antitumour effect of β2-microglobulin in leukemic cell-bearing mice via apoptosis-inducing activity: activation of caspase-3 and nuclear factor-κB. Cancer Res. (2001) 61(11):4414-4417.
83. HUANG Y, JOHNSON KR, NORRIS JS, FAN W: Nuclear factor-κB/IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumour cells. Cancer Res. (2000) 60(16):4426-4432.
84. BOURS V, BONIZZI G, BENTIRES-ALJ M et al.: NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicology (2000) 153(1-3):27-38.
85. WANG CY, CUSACK JC Jr, LIU R, BALDWIN ASJ: Control of inducible chemoresistance: enhanced antitumour therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. (1999) 5(4):412-417.
86. YANG J, RICHMOND A: Constitutive IκB kinase activity correlates with nuclear factor- κB activation in human melanoma cells. Cancer Res. (2001) 61(12):4901-4909.
87. HUANG S, DEGUZMAN A, BUCANA CD, FIDLER IJ: Nuclear factor-kappaB activity correlates with growth, angiogenesis and metastasis of human melanoma cells in nude mice. Clin. Cancer Res. (2000) 6(6):2573-2581.
88. KORDES U, KRAPPMANN D, HEISSMEYER V, LUDWIG WD, SCHEIDEREIT C: Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukaemia cells. Leukaemia (2000) 14(3):399-402.
89. UM JH, KANG CD, LEE BG et al.: Increased and correlated nuclear factor-κB and Ku autoantigen activities are associated with development of multi-drug resistance. Oncogene (2001) 20(42):6048-6056.
90. THORNTON JD, LIU R, ORLOWSKI RZ et al.: Doxorubicin-induced NF-κB activation in breast cancer is overcome by proteasome inhibition, resulting in enhanced tumouricidal response to treatment. 87th Annual Clinical Congress of the American College of Surgeons New Orleans, LA (October 7-12, 2001). Proceedings of ACS (2001).
91. PAJONK F, PAJONK K, MCBRIDE WH: Inhibition of NF-κB, clonogenicity and radiosensitivity of human cancer cells. J. Natl. Cancer Inst. (1999) 91(22):1956-1960.
92. SCHUTTE B, RAMAEKERS FC: Molecular switches that govern the balance between proliferation and apoptosis. Prog. Cell Cycle Res. (2000) 4:207-217.
93. JARPE MB, WIDMANN C, KNALL C et al.: Antiapoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. Oncogene (1998) 17(11 Reviews): 1475-1482.
94. ALMOND JB, SNOWDEN RT, HUNTER A et al.: Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700 kDa Apaf-1 containing apoptosome complex. Leukaemia (2001) 15(9):1388-1397.
95. NAUJOKAT C, SEZER O, ZINKE H et al.: Proteasome inhibitors induced caspase-dependent apoprosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur. J. Haematol. (2000) 65(4):221-236.
96. WAGENKNECHT B, HERMISSON M, GROSCURTH P et al.: Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J. Neurochem. (2000) 75(6):2288-2297.
97. LEBLANC R, CATLEY LP, HIDESHIMA T et al.: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. (2002) 62(17):4996-5000.
98. STEINER P, NEUMEIER H, LIGHTCAP ES et al.: Generation of PS-341-adapted human multiple myeloma cells as experimental tools for analysis of proteasome function in cancer. 43rd Annual Meeting of the American Society of Hematology Orlando, FL (Dec 7-11, 2001). Blood (2001) 98(11): 310a.
99. SUNWOO JB, CHEN Z, DONG G et al.: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumour growth and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. (2001) 7(5):1419-1428.
100. OHKAWA K, ASAKURA T, TAKADA K et al.: Calpain inhibitor causes accumulation of ubiquitinated P-glycoprotein at the cell surface: possible role of calpain in P-glycoprotein turnover. Int. J. Oncol. (1999) 15(4):677-686.
101. PALOMBELLA VJ, CONNER EM, FUSELER JW et al.: Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA (1998) 95(26):15671-15676.
102. PHILLIPS JB, WILLIAMS AJ, ADAMS J, ELLIOTT PJ, TORTELLA FC: Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischaemia. Stroke (2000) 31(7):1686-1693.
103. TAYLOR JR, HARDY J, FISCHBECK KH: Toxic proteins in neurodegenerative disease. Science (2002) 296(5575):1991-1995.
104. LAM YA, PICKART CM, ALBAN A et al.: Inhibition of the ubiquitin-proteasome system in Alzheimer's disease. Proc. Natl. Acad. Sci. USA (2000) 97(18):9902-9906.
105. LAYFIELD R: Does an inhibition of the ubiquitin/26S proteasome pathway of protein degradation underlie the pathogenesis of non-familial Alzheimer's disease? Med. Hypotheses (2001) 56(3):395-399.
106. LAYFIELD R, ALBAN A, MAYER RJ, LOWE J: The ubiquitin protein catabolic disorders. Neuropathol. Appl. Neurobiol. (2001) 27(3):171-179.
107. BENCE NF, SAMPAT RM, KOPITO RR: Impairment of the ubiquitin-proteasome system by protein aggregation. Science (2001) 292:(5521):1552-1555.
108. BOSSOLA M, MUSCARITOLI M, COSTELLI P et al.: Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am. J. Physiol. Regul. Integr. Comp Physiol. (2001) 280(5):R1518-R1523.
109. 2+ -activated and ubiquitin-proteasome proteolytic pathways. J. Clin. Invest. (1996) 97(7):1610-1617.
110. MITCH WE, BAILEY JL, WANG X et al.: Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am. J. Physiol (1999) 276(5 Pt 1):C1132-C1138.
111. PRICE SR, BAILEY JL, WANG X et al.: Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J. Clin. Invest. (1996) 98(8):1703-1708.
112. WILLIAMS A, SUN X, FISCHER JE, HASSELGREN PO: The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery (1999) 126(4):744-749.
113. WATCHORN TM, WADDELL I, DOWIDAR N, ROSS JA: Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J. (2001) 15(3):562-564.
114. LIGHTCAP ES, MCCORMACK TA, PIEN CS et al.: Proteasome inhibition measurements: clinical application. Clin. Chem. (2000) 46(5):673-683.
115. NIX D, PIEN C, MADEN T et al.: Clinical development of a proteasome inhibitor, PS-341, for the treatment of cancer. 37th Annual Meeting of the American Society of Clinical Oncology San Francisco, CA (May 12-15, 2001). Proceedings of the American Society of Clinical Oncology (2001) 20:86a.
116. AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumour malignancies. Clin Cancer Res. (2002) 8(8):2505-2511.
117. ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20:(21).
118. CLARK JW, RYAN D, DEES C et al.: Phase I dose-escalation study of the proteasome inhibitor, PS-341, plus irinotecan in patients with advanced solid tumours. Proceedings of the American Society of Clinical Oncology-38th Annual Meeting (2002) 21:93a.
119. RYAN DP, EDER JP, WINKLEMANN J et al.: Pharmacokinetic and pharmacodynamic Phase I study of PS-341 and gemcitabine in patients with advanced solid tumours. 38th Annual Meeting of the American Society of Clinical Oncology Orlando, FL (May 17-24, 2002). Proceedings of the American Society of Clinical Oncology (2002) 21:95a.
120. MEYER S, KOHLER NG, JOLY A: Cyclosporin A is an uncompetitive inhibitor of proteasome activity and prevents NF-κB activation. FEBS Lett. (1997) 413(2):354-358.
121. ANDRE P, GROETTRUP M, KLENERMAN P et al.: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation and T cell responses. Proc. Natl. Acad. Sci. USA (1998) 95:(22):13120-13124.
122. FIGUEIREDO-PEREIRA ME, CHEN WE, LI J, JOHDO O: The antitumour drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. J. Biol. Chem. (1996) 271(28):16455-16459.
123. RAO S, PORTER DC, HEN X et al.: Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl. Acad. Sci. USA (1999) 96(14):7797-7802.
124. NUSSBAUM AK, DICK TP, KEILHOLZ W et al.: Cleavage motifs of the yeast 20S proteasome β subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. USA (1998) 95(21):12504-12509.